What is ESWT?

Extracorporeal Shock Wave Therapy, (or ESWT), is a new technology using shockwaves to treat chronic, painful conditions of the musculoskeletal system. A shockwave is an intense, but very short energy wave traveling faster than the speed of sound. The word "Extra-corporeal" means "outside the body" and refers to the fact that the shockwaves are generated outside the body.

What is Shockwave Biosurgery?

Extracorporeal shockwave therapy (ESWT) is sometimes alternatively known as shockwave biosurgery, though ESWT isn't surgery as the word is usually defined or understood in North America.

What is the origin of ESWT?

The basic science behind ESWT is analogous to lithotripsy, the technology that uses acoustic shockwaves to break up kidney stones without surgery. The technique of using shockwaves to break up kidney stones has been around for a nearly a quarter century now, and in the process of treating thousands and thousands of patients, it was found that many people undergoing the procedure had other unrelated aches and pains disappear. It was at this point that scientists began to consider that shockwaves may have an effect to heal other sorts of tissues.

Specialized machines were then developed specifically with the idea of using these shockwaves on other parts of the body, and this is the origin of ESWT.

The type of shockwave therapy we use, then, is specialized to specifically help treat musculoskeletal conditions.

What conditions can you treat with ESWT?

Extracorporeal Shock Wave Therapy can be used to treat a wide variety of musculoskeletal conditions--particularly those involving where major connective tissues attach to bone.

Complaints involving attachment points for tendons and ligaments in major joints like the shoulder (such as the rotator cuff), elbow (epicondylitis or tennis elbow), hip, and knee (tendinitis or "jumper's knee) are common sites for ESWT.

One of the areas most frequently treated with ESWT, however, is the foot. This is our specialty. Some conditions in the foot that have been treated with ESWT include:

Plantar Fasciitis or Fasciosis (Strained Arch)
Achilles Tendinitis or Tendinosis
Calcific Tendinitis or Tendinosis
Connective Tissue Pain and degeneration
Muscle Pain and Injuries
Joint Injuries
Morton's Neuromas

And as ESWT encourages bone healing, it has been used to help treat:

Stress Fractures
Avascular Necrosis (A dead portion of bone)
Slow-healing bone (Delayed unions)
Non-healing bone (Non-unions)

Complex regional pain syndrome-like symptoms during herpes zoster

Abstract

Complex Regional Pain Syndrome (CRPS) associated with herpes zoster (HZ) was first reported by Sudeck in 1901 (Sudeck, 1901) and is recognized clinically. However, only 13 cases have been published in the literature, and nothing is known about the incidence, prevalence, or natural history (Chester, 1992; Foster et al., 1989; Grosslight et al., 1986; Ketz and Schliack,1968; Kishimoto et al., 1995; Querol and Cisneros, 2001;Sudeck, 1901; Visitsunthorn and Prete, 1981). The aim of the present study was to determine the prevalence of CRPS-like symptoms in a prospectively gathered cohort of subjects with HZ and to follow the natural history of their pain and sensory disturbance during the first 6 months after onset of HZ. Subjects were evaluated at four time points after HZ: 2-6 weeks, 6-8 weeks, 3 months, and 6 months. Only subjects aged 50 or older with pain VAS ratings of >/=20/100 at 2-6 weeks were eligible. The first (screening) visit included a neurological and physical examination that was updated at each subsequent visit. Assessments included ratings of pain intensity, allodynia severity, and rash severity. The neurological exam included determination of presence or absence of the following CRPS-like symptoms: (1) increased sweating, (2) color changes, (3) skin temperature changes, (4) weakness of the affected area based on physical exam, (5) edema, and (6) extension of CRPS-like symptoms outside the affected dermatome. For subjects with HZ in dermatomes that can include the limbs (C4-T2 and L1-S2), extremity involvement was considered present if allodynia or rash extended beyond the neck of the humerus (upper extremity), the inguinal ligament (anterior lower extremity), or gluteal sulcus (posterior lower extremity). Involvement of the extremity was considered proximal if neither HZ rash nor allodynia extended past the elbow (upper extremity) or knee (lower extremity). Of the first 75 subjects recruited, 25 had HZ outbreaks in dermatomes that extended into the extremities (C4-T2 and L1-S2). In this group, 8 subjects had no extremity involvement, 8 had proximal extremity involvement, and 9 had distal extremity involvement. Subjects with distal extremity HZ reported more pain across the four visits (p < 0.05). At 3 months, more subjects with distal extremity involvement met criteria for PHN (8 out of 9, 89%), while only 4 out of 8 (50%) with proximal involvement and 2 out of 8 (25%) of subjects without extremity involvement met criteria for PHN (Chi-square test: p < 0.05). Only 25 out of the remaining 50 (50%) subjects with outbreaks in dermatomes that do not include the extremities met criteria for PHN at 3 months (Chi-square test: p < 0.05). Six months after onset of HZ, 6 out of 9 subjects with distal extremity involvement met PHN criteria compared with 2 out of 8 (25%) with proximal involvement and 2 out of 8 (25%) without extremity involvement (Chi-square test: p = 0.12). Fifteen out of 50 (30%) subjects with outbreaks in dermatomes that do not include the extremities met criteria for PHN (Chi-square test: p < 0.05). No subject had all six CRPS-like symptoms. Of the 17 subjects with extremity involvement, 9 subjects had '0-2 CRPS-like symptoms' and 8 had '3-5 CRPS-like symptoms'. None of the eight subjects without extremity involvement had any CRPS-like symptoms. Of the 50 subjects with HZ outside the extremity, only one had abdominal weakness. Pain ratings were higher in subjects with '3-5 CRPS-like symptoms'. More subjects with '3-5 CRPS-like symptoms' met criteria for PHN at 3 months (7 out of 8, 88%), compared to 5 out of 9 (55%) of subjects with '0-2 CRPS-like symptoms' (p = 0.07). At 6 months, 2 out of 9 (22%) of subjects with '0-2 CRPS-like symptoms' met criteria for PHN, compared with 6 out of 8 (75%) of subjects with '3-5 CRPS-like symptoms' (Chi-square test: p < 0.03). Two case-reports are presented. In summary, the occurrence of CRPS-like symptoms is common in subjects with HZ outbreaks affecting the extremity, particularly if the distal extremity is involved. It is uncertain if the pathophysiology underlying the CRPS-like symptoms observed in this study is similar to that of CRPS from other causes, or if it is relatively specific to HZ. Development of PHN is common in subjects who have experienced CRPS-like symptoms. More aggressive preventive treatments may be justified in this high-risk subset of HZ subjects to prevent development of PHN. Prospective randomized controlled studies are needed to determine which subjects are most likely to benefit and when treatment should begin.

PMID:

 

15275746

 

[PubMed - indexed for MEDLINE]

Acquired immunodeficiency syndrome-related lymphoma

Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.

Abstract

BACKGROUND:

Highly active antiretroviral therapy (HAART) has improved the survival of patients with acquired immunodeficiency syndrome-related lymphoma (ARL). The German ARL Study Group investigated whether HAART administered concomitantly with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy compromised the course of immune parameters during and after chemotherapy and exerted a positive effect on remission and survival.

METHODS:

From 1997 to 2001, 72 patients with ARL were stratified prospectively into a standard-risk group (n = 48 patients) and a high-risk group (n = 24 patients) with either 0-1 or 2-3 of the following risk factors: CD4 < 50/microL, prior opportunistic infection, and/or a World Health Organization performance status > or = 3. Patients in the high-risk group received > or =75% of the CHOP regimen.

RESULTS:

In the standard-risk group (CD4 = 223/muL; age-adjusted International Prognostic Index [aaIPI], 38% > or = 2), the complete remission (CR) rate was 79%, and median survival was not reached after a median 47 months of follow-up. CD4 counts did not change from baseline to 4 weeks after the end of chemotherapy (206/microL). In the high-risk group (CD4 = 34/muL; aaIPI, 88% > or = 2), the CR rate was 29%, and the median survival was 7.2 months (3 patients survived for > 3 yrs). Toxicity was moderate: Leukopenia Grade 3 or 4 occurred in 100 of 249 chemotherapy cycles (40%) in the standard-risk group and in 70 of 102 cycles (69%) in the high-risk group.

CONCLUSIONS:

Based on the aaIPI, the survival of patients in the standard-risk group was very similar to that achieved by nonhuman immunodeficiency virus-infected patients who had aggressive lymphomas. Concurrent CHOP plus HAART can be administered in an outpatient setting. Thus, the authors recommend using this modality as first-line therapy for patients with ARL.

Copyright 2006 American Cancer Society.

PMID:

 

16502436

 

[PubMed - indexed for MEDLINE] 

Complex regional pain syndrome versus chronic regional pain syndrome (Hand-Finger Syndrome)

Abstract

Dystrophy is a main factor of CRPS. A large number of patients do not develop dystrophy but, instead, they suffer from pain with limitation in movement, possible paraesthesia and/or swelling. This is then a chronic regional pain syndrome or (shoulder-arm-) hand-finger syndrome. These patients should never be confronted with the diagnosis Morbus Sudeck or algodystrophy, which are today also well known among non-professionals, to avoid pushing them into a status of constant severe invalidity. Histories, clinical examination, as well as a good personal understanding of the patient are indispensable. Knowing that pain, or the extent of pain, remains subjective until today, the clinical diagnosis depends on the absence of side differences in: a) the circumference of soft tissues of both upper extremities; b) the callosity of the palm; c) the bone-density. These three parameters allow verification of the consequences of the pain complaints (indirect pain verification). It is essential to find the cause for their suffering and to treat it as far as possible: 1) Too long and inappropriate immobilisation (patient's suffering not considered sufficiently). These patients can recover quickly when the right diagnosis is made in good time. 2) Limitation of movement due to scar, neuroma, or elongation pain: a) bizarre functional disabilities can develop; b) due to the patient's complaints, one or several operations would finally be performed, which will not lead to an improvement but rather to an aggravation of the pain; c) socially-induced purposeful pain increase, the typical statement of the patient will be: "I can't stand it any longer". Patients who are socially over-burdened, or have psycho-social problems, may experience a decline of performance or a post-traumatic stress disorder. Several patients will be introduced as illustrations for each of the relevant groups.

Georg Thieme Verlag KG Stuttgart, New York.

PMID:

 

20205065

 

[PubMed - indexed for MEDLINE]

Sudeck syndrome (CRPS) caused by unique personality traits: myth and fiction

In analogy to the thesis of "pain-proneness", conceptualised by G. Engel more than 50 years ago, the idea of a unique structure in personality emerged, which was given a causal meaning in the development of Sudeck's Disease (now known as complex regional pain syndrome - CRPS), of which the pathogenesis is particularly unknown until today. It was supposed that certain psychological traits predispose one to develop CRPS. Predisposition in this context was apprehended as a personal susceptibility to produce and maintain an excessive reaction to nociceptive stimulations. This model has been maintained for a long time and was the subject of scientific examination just in the last two decades.

METHOD:

Some publications reporting sporadic correlations between CRPS and certain personality traits, for example anxiety, neuroticism and depressive mood, are presented as are also 15 current empirical studies and five reviews, which deal in a more differentiated manner with the formulated question and lead to sobering results. The relevant state of research as well as the fundamental and methodical difficulties in regard to verifying a CRPS personality or pain-prone personality are discussed critically.

RESULTS:

In general, there is a lack of high-quality relevant studies. Some retrospective/cross-sectional studies yield contradictory results regarding psychological problems in patients with CRPS but the majority shows no association, and studies with higher methodological quality tend to the conclusion of no relationship between psychological factors like depression, anxiety, neuroticism, or anger and CRPS. Especially, the few prospective studies do not report such a relationship, psychological factors are not associated with CRPS onset. Compared to other patients with chronic pain there is no unique disturbed psychological profile and no higher degree of psychosocial disturbance in CRPS patients. In all, the results of research cannot confirm the hypothesis of correlations between psychological and psychosocial factors and the pathogenesis of CRPS. Furthermore, there is no evidence for the existence of a unique CRPS personality or psychosocial pattern. The findings are in conformity with the outcome of research referring to the general pain-prone personality, which was abandoned due to the lack of success. It has been shown that there is a non-specific and non-linear relationship between personality and pain, there is no aetiological link. The observed modifications in behaviour and personality of CRPS patients, in particular depression and anxiety, are a consequence of the persisting pain disease and its considerable resistance towards treatment and not the cause.

CONCLUSION:

Although many patients with CRPS have been stigmatised as being psychologically different, a relationship between this disease and several psychological factors cannot be derived. The idea of an existing "Sudeck personality" as well as the search for such a predisposing personality structure are obsolete and useless. Management of pain and pain-related impairments, however, are based on the personality of the affected persons.

© Georg Thieme Verlag KG Stuttgart · New York.

PMID:

 

20941689

 

[PubMed - indexed for MEDLINE]

From Morbus Sudeck to complex regional pain syndrome

Abstract

Burning pain and autonomic disorders, such as change of skin color, hyperhidrosis, edema and stiffness in joints of extremities were first described in 1864 by Silas W. Mitchell. The German expression "MorbusSudeck" takes its name from the surgeon Paul Sudeck from Hamburg who described spotty decalcification in x-rays in 1900. In the Anglo-Saxon world, the theory that the sympathetic nervous system was involved in the generation and sustention of these alterations was based on the observations of the French surgeon René Leriche and in 1846 James A. Evans introduced the expression sympathetic reflex dystrophy. As doubts arose that the sympathetic nervous system could not be the sole culprit, the descriptive phrase of complex regional pain syndrome was introduced to substitute for more than 60 synonyms focusing on the fact that the disease develops after minor trauma or nerve lesions and does not correlate with the severity of the trauma. Diagnosing this syndrome is still hampered by the fact that no specific laboratory or radiological marker has yet been identified. Multidisciplinary and interdisciplinary approaches to therapy seem to be inevitable. SinceSudeck first described the disease, 110 years have passed. The underlying hypothesis and theories as well as the development during this time period are summarized.

© Deutsche Gesellschaft zum Studium des Schmerzes

Complex regional pain syndrome acceptance and the alternative denominations in the medical literature.

Abstract

OBJECTIVE:

To analyze the use of the term 'complex regional pain syndrome' in the medical literature and evaluate whether or not the traditional names 'reflex sympathetic dystrophy' and 'causalgia' have already been replaced with the new terms 'complex regional pain syndrome type I' and 'complex regional pain syndrometype II', respectively.

MATERIALS AND METHODS:

The Scopus and PubMed databases were searched for reports written between 2001 and 2012 for the following descriptors in the titles: 'complex regional pain syndrome', 'complex regional pain syndrome type I', 'complex regional pain syndrome type 1', 'complex regional pain syndrome type II', 'complex regional pain syndrome type 2', 'CRPS', 'CRPS type I', 'CRPS type 1', 'CRPS type II', 'CRPS type 2', 'reflex sympathetic dystrophy', 'algodystrophy', 'algoneurodystrophy', 'causalgia', 'transient osteoporosis', 'Sudeck', and 'shoulder-hand syndrome'.

RESULTS:

Systematization of the 1,318 articles found yielded the following: 953 (72.31%) articles for the descriptor 'complex regional pain syndrome' and a further 94 (7.13%) for its abbreviation 'CRPS'; 180 (13.66%) for 'reflex sympathetic dystrophy'; 33 (2.50%) for 'shoulder-hand syndrome'; 29 (2.20%) for 'algodystrophy'; 13 (0.99%) for 'causalgia'; 13 (0.99%) for 'Sudeck'; 2 (0.15%) for 'algoneurodystrophy', and 1 (0.08%) for 'transient osteoporosis'. The total number of articles using new terminology represents 1,047 (79.44%) of all articles.

CONCLUSION:

The new neutral term 'complex regional pain syndrome' was most commonly used and will likely replace the traditional names 'reflex sympathetic dystrophy' and 'causalgia'. The new terminology is now widely accepted by the medical professionals who are mostly engaged in the treatment of CRPS patients, but not yet so in other medical spheres.

Copyright © 2012 S. Karger AG, Basel.

PMID:

 

23171669

 

[PubMed - indexed for MEDLINE]